Combination therapy of DPP-4 inhibitor and metformin: Rationality and its evidence
10.3760/cma.j.issn.1000-6699.2012.12.022
- VernacularTitle:DPP-4抑制剂与二甲双胍联合治疗的合理性及其研究证据
- Author:
Ye LIU
;
Tianpei HONG
- Publication Type:Journal Article
- Keywords:
Dipeptidyl peptidase-4 inhibitor;
Metformin;
Glucagon-like peptide-1;
Combination therapy;
Mechanism
- From:
Chinese Journal of Endocrinology and Metabolism
2012;(12):1033-1035
- CountryChina
- Language:Chinese
-
Abstract:
Metformin improves glycemic control mainly due to improved insulin sensitivity.Dipeptidyl peptidase-4(DPP-4) inhibitor,which suppresses degradation of glucagon-like peptide-1 (GLP-1) and maintains the bioactivity of endogenous GLP-1,improves islet dysfunction.Moreover,recent studies suggested that metformin enhanced the biological effect of GLP-1 via different mechanisms and that DPP-4 inhibitor enhanced insulin sensitivity in type 2 diabetes.Therefore,the combination therapy of DPP-4 inhibitor and metformin could simultaneously ameliorate the two major defects of type 2 diabetes and obtain complementary and synergistic benefits for glycemic control.
